Markets:

Overview

News

Currencies

International

Treasuries

Longeveron Inc. - Class A Common stock (NQ:LGVN)

0.8630 +0.0758 (+9.63%)

Streaming Delayed Price Updated: 11:13 AM EDT, Aug 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 04, 2021

Gainers Longeveron (NASDAQ:LGVN) shares ...

Via Benzinga

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

October 04, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Initial Public Offering Lawsuit

Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment ↗

October 04, 2021

Research and development of stem cell-based therapies, where a patient’s own cells, or those from a donor, are used to fight injury and disease, is one of the fastest...

Via Benzinga

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗

August 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...

Via Benzinga

Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity ↗

September 29, 2021

Lomecel-B significantly decreased biomarker Tie-2 in Aging Frailty subjects at 270 days compared to placebo Significant, dose-dependent decrease in Tie-2 at Day 270 Oral...

Via Benzinga

NASDAQ:LGVN Investor Notice: Lawsuit Alleges Securities Laws Violations by Longeveron Inc. ↗

September 29, 2021

San Diego, CA -- (SBWIRE) -- 09/29/2021 -- An investor, who purchased shares of Longeveron Inc. (NASDAQ:LGVN), filed a lawsuit over alleged violations of Federal Securities Laws by Longeveron Inc. in...

Via SBWire

Topics Initial Public Offering Lawsuit Regulatory Compliance

EXCLUSIVE: Longeveron Announces Biomarker Analysis Data From Mid-Stage Study Of Anti-Aging Cell Therapy Candidate ↗

September 29, 2021

Longeveron Inc. (NASDAQ: LGVN) announced Wednesday positive biomarker analysis data from the mid-stage study of its lead cell therapy candidate in aging frailty subjects. What...

Via Benzinga

LONGEVERON ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Longeveron Inc. and Encourages Investors to Contact the Firm

September 17, 2021

From Bragar Eagel & Squire, P.C.

Via Business Wire

SHAREHOLDER ALERT: Robbins LLP Announces that Longeveron Inc. (LGVN) is Being Sued for Misleading Shareholders

September 17, 2021

From Robbins LLP

Via Business Wire

Heart Hope: Announcing the Encouraging Results of a Cell-Therapy Clinical Study by Longeveron ↗

September 15, 2021

Photo by jesse orrico on Unsplash Researchers in the medical field are constantly working to create medicines to prevent and cure diseases. The development of the multiple COVID-...

Via Benzinga

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

September 15, 2021

From The Schall Law Firm

Via Business Wire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

September 14, 2021

From The Schall Law Firm

Via Business Wire

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Longeveron Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – LGVN

September 14, 2021

From Rosen Law Firm

Via Business Wire

Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients ↗

September 09, 2021

--Study meets primary safety endpoint: no major adverse cardiac events (MACE), nor any treatment-related infections during the first month post-treatment. --Secondary...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 09, 2021

Gainers Soligenix (NASDAQ:SNGX) stock increased by 22.85% to $1.29 during Thursday's pre-market session. The company's market cap stands at $51.7 million. Cardiff...

Via Benzinga

EXCLUSIVE: Longeveron's Lomecel-B Cell Therapy Meets Primary Safety Endpoint In Phase 1 Rare Congenital Heart Disease Study ↗

September 09, 2021

Longeveron Inc. (NASDAQ: LGVN), a cell therapy company developing therapies for age-related and life-threatening conditions, reported Thursday final results from a Phase 1 study...

Via Benzinga

NASDAQ:LGVN Investor Notice: Investigation over Possible Securities Laws Violations by Longeveron Inc. ↗

September 02, 2021

San Diego, CA -- (SBWIRE) -- 09/02/2021 -- Longeveron Inc is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

38 Stocks Moving In Monday's Mid-Day Session ↗

August 16, 2021

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares climbed 34.5% to $3.3900 after the company announced plan to expand product portfolio with introduction of Painshield relief for...

Via Benzinga

The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal ↗

August 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (...

Via Benzinga

24 Stocks Moving in Monday's Pre-Market Session ↗

August 16, 2021

Gainers Enlivex Therapeutics Ltd. (NASDAQ: ENLV) shares rose 26.6% to $12.87 in pre-market trading after the company disclosed that after reviewing its earlier-reported Phase II...

Via Benzinga

60 Biggest Movers From Yesterday ↗

August 17, 2021

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product portfolio with introduction of...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

August 13, 2021

Gainers Biolase (NASDAQ:BIOL) stock increased by 38.01% to $0.87 during Friday's regular session. Trading volume for this security as of 12:35 EST is 80.8 million,...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

August 16, 2021

On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap to set a new 52-week low was Koninklijke Philips (NYSE...

Via Benzinga

78 Biggest Movers From Friday ↗

August 16, 2021

Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering. Flora Growth...

Via Benzinga

August 13, 2021

Via FinancialNewsMedia

53 Stocks Moving In Friday's Mid-Day Session ↗

August 13, 2021

Gainers BIOLASE, Inc. (NASDAQ: BIOL) shares climbed 30.9% to $0.8270 after the company reported better-than-expected Q2 sales. The company said it continues to experience demand...

Via Benzinga

EXCLUSIVE: Longeveron Spikes As Lead Drug Produces Dose-Dependent Response In Aging Frailty Study; Primary Endpoint Not Met ↗

August 13, 2021

Florida-based biopharma Longeveron Inc. (NASDAQ: LGVN), which is engaged in the development of cell therapies for chronic age-related and life-threatening conditions, announced...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

August 13, 2021

Friday morning, 94 companies reached new 52-week lows. Significant Points: Wix.com (NASDAQ:WIX) is the largest company in terms of market cap to set a new 52-week...

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.